AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.185
-0.005 (-2.63%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.190
Open0.195
Bid0.170 x 0
Ask0.185 x 0
Day's Range0.185 - 0.200
52 Week Range0.150 - 0.450
Volume96,571
Avg. Volume99,425
Market Cap14.881M
Beta (3Y Monthly)-0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.043
Earnings DateNov 27, 2018 - Dec 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire2 months ago

    Aequus Reports 5th Consecutive Quarter of Revenue Growth

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended June 30, 2018 (“Q2 2018”) and associated Company developments. Subsequent to the end of the quarter, the Company successfully closed two financings with total proceeds of $1,575,000.

  • GlobeNewswire2 months ago

    Aequus Closes Balance of $775,000 Equity Financing

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it has closed the balance of a non-brokered private placement announced August 9, 2018 for an aggregate 3,875,000 units of the Company (the “Units”) at a price of $0.20 per Unit (the “Offering Price”), for aggregate gross proceeds of $775,000 (the “Private Placement”). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”).

  • GlobeNewswire2 months ago

    Aequus Announces Fully-subscribed $775,000 Equity Financing

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a non-brokered private placement (the “Placement”) of 3,875,000 units of the Company (the “Units”) at a price of $0.20 per Unit (the “Offering Price”), for aggregate gross proceeds of $775,000 (the “Private Placement”). Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”).

  • GlobeNewswire3 months ago

    Aequus Announces Closing of $800,000 Equity Financing

    NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. VANCOUVER, British Columbia, July 31, 2018-- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on ...

  • GlobeNewswire3 months ago

    Issuance of Stock Options

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), Aequus is pleased to announce it has granted incentive stock options to Damien King, a new director of the Company for the right to purchase up to an aggregate of 350,000 common shares of the Company. The terms of the stock options granted on July 23, 2016 are in accordance with the Company’s Stock Option Plan. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.

  • GlobeNewswire3 months ago

    Aequus Announces Proposed $800,000 Equity Financing To Next Edge Biotech Plus Fund

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a proposed equity financing of 4,000,000 units of the Company (the "Units") at a price of $0.20 per Unit (the "Offering Price"), for aggregate gross proceeds of $800,000 (the "Offering") to the Next Edge Bio-Tech Plus Fund under a prospectus supplement to the Company’s base shelf prospectus dated August 15, 2017, which prospectus supplement will be filed in the provinces of British Columbia, Alberta, Ontario, Saskatchewan and Manitoba. Each Unit shall consist of one common share of the Company and one-half of one non-transferrable common share purchase warrant (each, a "Warrant").

  • Baystreet6 months ago

    Big Pharma says It Must Collaborate with Juniors to Revive Real Innovation

    Innovation in the pharmaceutical industry has come a long way in the last few decades, but with the ...

  • Baystreet7 months ago

    Drug Makers Use Nanotechnology to Improve Delivery and Dosing

    In order to advance the delivery of specialized medicines and dosage, scientists are looking to improvements ...

  • PR Newswire8 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.

  • CNW Group8 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (TSX-V:AQS.V - News) (OTCQB:AQSZF - News) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB:EHVVF - News) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.